APA (7th ed.) Citation

T, C., J, B., J, V. D. W., R, K., J, C., L, K., & M, E. (2025). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT-787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial. Clinical and translational science, 18(5), e70229. https://doi.org/10.1111/cts.70229

Chicago Style (17th ed.) Citation

T, Capozza, Burkey J, Van De Wetering J, Kerb R, Callahan J, Kryzhanovskaya L, and Erickson M. "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT-787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial." Clinical and Translational Science 18, no. 5 (2025): e70229. https://doi.org/10.1111/cts.70229.

MLA (9th ed.) Citation

T, Capozza, et al. "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT-787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial." Clinical and Translational Science, vol. 18, no. 5, 2025, p. e70229, https://doi.org/10.1111/cts.70229.